KURA — Kura Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422143 ·
Last close
$11.25
Market Cap
$998.71M
52W High
$11.52
52W Low
$7.53
ADV30
1,628,353
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 18,265,000 | 18,003,000 | -78,815,000 | -73,333,000 | 652,551,000 | 39,083,000 | 544,668,000 |
| Dec 2025 | 17,336,000 | — | -86,268,000 | -80,999,000 | 738,363,000 | 149,099,000 | 564,228,000 |
| Sep 2025 | 20,750,000 | — | -79,997,000 | -74,116,000 | 649,381,000 | 95,287,000 | 406,839,000 |
| Jun 2025 | 15,288,000 | — | -72,666,000 | -66,122,000 | 682,425,000 | 81,948,000 | 376,939,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,058,000
Investing CF
$-13,098,000
Financing CF
$1,793,000
CapEx
$-6,638,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.18
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,174,088,000
Inventory
$413,000
Receivables
$8,804,000
ST Investments
$518,141,000
EBIT TTM
$-276,857,000
Pretax Income TTM
$-278,369,000
Interest Exp TTM
$1,512,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,639,000
EBITDA
$-316,600,000
Free Cash Flow
$-129,832,496
Enterprise Value
$442,161,600
Total Cash
$580,822,976
Total Debt
$24,273,000
Shares Out
88,774,365
Trailing EPS
$-3.35
Book Value
$1.22
ROE
-124.7%
ROA
-28.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,482,000 | -303,631,000 | -278,666,000 | 738,363,000 | 564,228,000 | — | -64,058,000 |
| Dec 2024 | 53,883,000 | -193,195,000 | -173,983,000 | 760,159,000 | 346,519,000 | — | 134,317,000 |
| Dec 2023 | 0 | -165,804,000 | -152,631,000 | 448,935,000 | 51,662,000 | — | -124,824,000 |
| Dec 2022 | 0 | -139,865,000 | -135,840,000 | 456,306,000 | 36,028,000 | — | -110,062,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.55
Max Pain — expiry 2026-06-18
max pain strike: $10.00 · spot: $10.41 · call oi: 6,755 · put oi: 614
Expected Move to 2026-06-18:
±$1.92
(18.49%) —
implied range
$8.48 –
$12.33
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SVRA | Savara Inc | $1.03B | $5.02 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $959.46M | $2.16 | — |
| OPK | OPKO HEALTH, INC. | $958.97M | $1.27 | — |
| MNKD | MANNKIND CORP | $1.04B | $3.38 | — |
| IVA | Inventiva S.A. | $1.06B | $5.07 | — |
News headlines (Yahoo Finance, 1h cache)
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
2026-05-26 10:02 · Yahoo
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
2026-05-19 20:02 · Yahoo
Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
2026-05-17 13:22 · Yahoo
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts
2026-05-15 13:10 · Yahoo
Kura Oncology, Inc. Q1 2026 Earnings Call Summary
2026-05-13 12:30 · Yahoo
Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising ...
2026-05-13 05:02 · Yahoo
Kura Oncology Q1 Earnings Call Highlights
2026-05-13 01:09 · Yahoo
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:15 · Yahoo
Kura Oncology Reports First Quarter 2026 Financial Results
2026-05-12 20:02 · Yahoo
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
2026-05-12 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.